Gilead Sciences (GILD) Free Cash Flow (2009 - 2026)
Gilead Sciences posted quarterly Free Cash Flow of $2.4 billion for Q1 2026, up 46.82% year-on-year from $1.7 billion in Q1 2025, and down 22.26% on a QoQ basis from $3.1 billion in Q4 2025.
Gilead Sciences (GILD) has 18 years of Free Cash Flow data on file, last reported at $2.4 billion in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 46.82% year-over-year to $2.4 billion; the trailing twelve-month figure through Mar 2026 stood at $10.2 billion (up 3.92% YoY), and the FY2025 full-year result was $9.5 billion, down 8.24% from the prior year.
- Free Cash Flow for Q1 2026 stood at $2.4 billion, down from $3.1 billion in the prior quarter.
- Across five years, Free Cash Flow topped out at $4.2 billion in Q3 2024 and bottomed at $720.0 million in Q2 2025.
- The 5-year median for Free Cash Flow is $2.1 billion (2024), against an average of $2.2 billion.
- Peak annual rise in Free Cash Flow reached 155.24% in 2024, while the deepest fall reached 45.66% in 2024.
- A 5-year view of Free Cash Flow shows it stood at $2.4 billion in 2022, then decreased by 18.11% to $2.0 billion in 2023, then soared by 44.73% to $2.8 billion in 2024, then gained by 10.4% to $3.1 billion in 2025, then dropped by 22.26% to $2.4 billion in 2026.
- The last three Free Cash Flow figures came in at $2.4 billion (Q1 2026), $3.1 billion (Q4 2025), and $4.0 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 346.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.01 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 1.47 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 3.56 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 2.93 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.48 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.43 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.18 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 757.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.43 Bn |
| Mar 31, 2026 | 2.43 Bn |
| Dec 31, 2025 | 3.12 Bn |
| Dec 31, 2025 | 3.12 Bn |
| Sep 30, 2025 | 3.96 Bn |
| Sep 30, 2025 | 3.96 Bn |
| Jun 30, 2025 | 720.00 Mn |
| Jun 30, 2025 | 720.00 Mn |
| Mar 31, 2025 | 1.65 Bn |
| Mar 31, 2025 | 1.65 Bn |
| Dec 31, 2024 | 2.83 Bn |
| Dec 31, 2024 | 2.83 Bn |
| Sep 30, 2024 | 4.17 Bn |
| Sep 30, 2024 | 4.17 Bn |
| Jun 30, 2024 | 1.20 Bn |
| Jun 30, 2024 | 1.20 Bn |
| Mar 31, 2024 | 2.11 Bn |
| Mar 31, 2024 | 2.11 Bn |
| Dec 31, 2023 | 1.95 Bn |
| Dec 31, 2023 | 1.95 Bn |
| Sep 30, 2023 | 1.63 Bn |
| Sep 30, 2023 | 1.63 Bn |
| Jun 30, 2023 | 2.20 Bn |
| Jun 30, 2023 | 2.20 Bn |
| Mar 31, 2023 | 1.64 Bn |
| Mar 31, 2023 | 1.64 Bn |
| Dec 31, 2022 | 2.39 Bn |
| Dec 31, 2022 | 2.39 Bn |
| Sep 30, 2022 | 2.71 Bn |
| Sep 30, 2022 | 2.71 Bn |
| Jun 30, 2022 | 1.66 Bn |
| Jun 30, 2022 | 1.66 Bn |
| Mar 31, 2022 | 1.59 Bn |
| Mar 31, 2022 | 1.59 Bn |
| Dec 31, 2021 | 3.05 Bn |
| Dec 31, 2021 | 3.05 Bn |
| Sep 30, 2021 | 3.11 Bn |
| Sep 30, 2021 | 3.11 Bn |
| Jun 30, 2021 | 2.20 Bn |
| Jun 30, 2021 | 2.20 Bn |
| Mar 31, 2021 | 2.45 Bn |
| Mar 31, 2021 | 2.45 Bn |
| Dec 31, 2020 | 1.74 Bn |
| Dec 31, 2020 | 1.74 Bn |
| Sep 30, 2020 | 2.10 Bn |
| Sep 30, 2020 | 2.10 Bn |
| Jun 30, 2020 | 2.42 Bn |
| Jun 30, 2020 | 2.42 Bn |
| Mar 31, 2020 | 1.27 Bn |
| Mar 31, 2020 | 1.27 Bn |
| Dec 31, 2019 | 2.38 Bn |
| Dec 31, 2019 | 2.38 Bn |
| Sep 30, 2019 | 2.45 Bn |
| Sep 30, 2019 | 2.45 Bn |
| Jun 30, 2019 | 2.16 Bn |
| Jun 30, 2019 | 2.16 Bn |
| Mar 31, 2019 | 1.34 Bn |
| Mar 31, 2019 | 1.34 Bn |
| Dec 31, 2018 | 2.10 Bn |
| Dec 31, 2018 | 2.10 Bn |
| Sep 30, 2018 | 2.05 Bn |
| Sep 30, 2018 | 2.05 Bn |
| Jun 30, 2018 | 1.28 Bn |
| Jun 30, 2018 | 1.28 Bn |
| Mar 31, 2018 | 2.06 Bn |
| Mar 31, 2018 | 2.06 Bn |
| Dec 31, 2017 | 2.53 Bn |
| Dec 31, 2017 | 2.53 Bn |
| Sep 30, 2017 | 2.57 Bn |
| Sep 30, 2017 | 2.57 Bn |
| Jun 30, 2017 | 3.40 Bn |
| Jun 30, 2017 | 3.40 Bn |
| Mar 31, 2017 | 2.81 Bn |
| Mar 31, 2017 | 2.81 Bn |
| Dec 31, 2016 | 3.37 Bn |
| Dec 31, 2016 | 3.37 Bn |
| Sep 30, 2016 | 4.20 Bn |
| Sep 30, 2016 | 4.20 Bn |
| Jun 30, 2016 | 4.78 Bn |
| Jun 30, 2016 | 4.78 Bn |
| Mar 31, 2016 | 3.95 Bn |
| Mar 31, 2016 | 3.95 Bn |
| Dec 31, 2015 | 5.63 Bn |
| Dec 31, 2015 | 5.63 Bn |
| Sep 30, 2015 | 3.81 Bn |
| Sep 30, 2015 | 3.81 Bn |
| Jun 30, 2015 | 5.49 Bn |
| Jun 30, 2015 | 5.49 Bn |
| Mar 31, 2015 | 5.58 Bn |
| Mar 31, 2015 | 5.58 Bn |
| Dec 31, 2014 | 2.85 Bn |
| Dec 31, 2014 | 2.85 Bn |
| Sep 30, 2014 | 3.91 Bn |
| Sep 30, 2014 | 3.91 Bn |
| Jun 30, 2014 | 4.09 Bn |
| Jun 30, 2014 | 4.09 Bn |
| Mar 31, 2014 | 1.40 Bn |
| Mar 31, 2014 | 1.40 Bn |
| Dec 31, 2013 | 658.11 Mn |
| Dec 31, 2013 | 658.11 Mn |
| Sep 30, 2013 | 715.92 Mn |
| Sep 30, 2013 | 715.92 Mn |
| Jun 30, 2013 | 907.73 Mn |
| Jun 30, 2013 | 907.73 Mn |
| Mar 31, 2013 | 633.25 Mn |
| Mar 31, 2013 | 633.25 Mn |
| Dec 31, 2012 | 436.19 Mn |
| Dec 31, 2012 | 436.19 Mn |
| Sep 30, 2012 | 678.78 Mn |
| Sep 30, 2012 | 678.78 Mn |
| Jun 30, 2012 | 1.25 Bn |
| Jun 30, 2012 | 1.25 Bn |
| Mar 31, 2012 | 429.77 Mn |
| Mar 31, 2012 | 429.77 Mn |
| Dec 31, 2011 | 952.00 Mn |
| Dec 31, 2011 | 952.00 Mn |
| Sep 30, 2011 | 832.82 Mn |
| Sep 30, 2011 | 832.82 Mn |
| Jun 30, 2011 | 916.62 Mn |
| Jun 30, 2011 | 916.62 Mn |
| Mar 31, 2011 | 805.67 Mn |
| Mar 31, 2011 | 805.67 Mn |
| Dec 31, 2010 | 701.48 Mn |
| Dec 31, 2010 | 701.48 Mn |
| Sep 30, 2010 | 728.62 Mn |
| Sep 30, 2010 | 728.62 Mn |
| Jun 30, 2010 | 683.03 Mn |
| Jun 30, 2010 | 683.03 Mn |
| Mar 31, 2010 | 658.90 Mn |
| Mar 31, 2010 | 658.90 Mn |
| Dec 31, 2009 | 928.29 Mn |
| Dec 31, 2009 | 928.29 Mn |
| Sep 30, 2009 | 842.41 Mn |
| Sep 30, 2009 | 842.41 Mn |
| Jun 30, 2009 | 602.04 Mn |
| Jun 30, 2009 | 602.04 Mn |
| Mar 31, 2009 | 477.26 Mn |
| Mar 31, 2009 | 477.26 Mn |